Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed multiple myeloma, Stage II-III as per Salmon and Durie (1975)~* Indication for biphosphonate therapy~Exclusion Criteria:~* Previous therapy with ibandronate or zoledronate within the past 12 months~* Renal insufficiency with serum creatinine \>3.0 mg/dL or \>265 micromoles per liter (µmol/L) or CrCl \<30 mL/min~* Hypersensitivity to ibandronate, zoledronate, or other biphosphonates~* Presence of secondary malignomas, apart from basaliomas and cervical carcinoma in situ~* Severe accompanying illness with organ impairment~* Osteonecrosis of the jaw at the start of the study~* Life expectancy ≤12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ibandronate (Type: EXPERIMENTAL): Participants with multiple myeloma will be randomized to receive ibandronate every 4 weeks for a planned duration of 92 weeks.
- Zoledronate (Type: ACTIVE_COMPARATOR): Participants with multiple myeloma will be randomized to receive zoledronate every 4 weeks for a planned duration of 92 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).